Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry- based cohort study
dc.contributor.author | Barnes, Geoffrey D. | |
dc.contributor.author | Li, Yun | |
dc.contributor.author | Gu, Xiaokui | |
dc.contributor.author | Haymart, Brian | |
dc.contributor.author | Kline‐rogers, Eva | |
dc.contributor.author | Ali, Mona A. | |
dc.contributor.author | Kozlowski, Jay | |
dc.contributor.author | Krol, Gregory | |
dc.contributor.author | Froehlich, James B. | |
dc.contributor.author | Kaatz, Scott | |
dc.date.accessioned | 2020-08-10T20:53:09Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2020-08-10T20:53:09Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Barnes, Geoffrey D.; Li, Yun; Gu, Xiaokui; Haymart, Brian; Kline‐rogers, Eva ; Ali, Mona A.; Kozlowski, Jay; Krol, Gregory; Froehlich, James B.; Kaatz, Scott (2020). "Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry- based cohort study." Journal of Thrombosis and Haemostasis 18(8): 2025-2030. | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.issn | 1538-7836 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/156139 | |
dc.description.abstract | BackgroundUse of bridging anticoagulation increases a patient’s bleeding risk without clear evidence of thrombotic prevention among warfarin- treated patients with atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin- treated patients with venous thromboembolism (VTE) has not been studied.MethodsWe identified warfarin- treated patients with VTE who temporarily stopped warfarin for a surgical procedure between 2010 and 2018 at six health systems. Using the 2012 American College of Chest Physicians guideline, we assessed use of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent VTE risk and 30- day outcomes (bleeding, thromboembolism, emergency department visit) were each assessed using logistic regression adjusted for multiple procedures per patient.ResultsDuring the study period, 789 warfarin- treated patients with VTE underwent 1529 procedures (median, 2; interquartile range, 1- 4). Unadjusted use of bridging anticoagulation was more common in patients at high risk for VTE recurrence (99/171, 57.9%) than for patients at moderate (515/1078, 47.8%) or low risk of recurrence (134/280, 47.86%). Bridging anticoagulation use was higher in high- risk patients compared with low- or moderate- risk patients in both unadjusted (PÂ =Â .013) and patient- level cluster- adjusted analyses (PÂ =Â .031). Adherence to American College of Chest Physicians guidelines in high- and low- risk patients did not change during the study period (odds ratio, 0.98 per year; 95% confidence interval, 0.91- 1.05). Adverse events were rare and not statistically different between the two treatment groups.ConclusionsBridging anticoagulation was commonly overused among low- risk patients and underused among high- risk patients treated with warfarin for VTE. Adverse events were rare and not different between the two treatment groups. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | warfarin | |
dc.subject.other | venous thromboembolism | |
dc.subject.other | perioperative | |
dc.subject.other | low- molecular- weight | |
dc.subject.other | heparin | |
dc.subject.other | anticoagulation | |
dc.title | Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry- based cohort study | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156139/2/jth14903_am.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156139/1/jth14903.pdf | en_US |
dc.identifier.doi | 10.1111/jth.14903 | |
dc.identifier.source | Journal of Thrombosis and Haemostasis | |
dc.identifier.citedreference | Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS- PE Randomized Clinical Trial. JAMA. 2015; 314: 31 - 40. | |
dc.identifier.citedreference | Middeldorp S, Hutten BA. Long- term vs short- term therapy with vitamin K antagonists for symptomatic venous thromboembolism. JAMA. 2015; 314: 72 - 73. | |
dc.identifier.citedreference | Barnes GD, Seiler K, Brady P, Kamdar N. Nation- wide use of periprocedural bridging anticoagulation in patients with atrial fibrillation. Am J Cardiol. 2019; 124: 1549 - 1553. | |
dc.identifier.citedreference | Barnes GD, Li Y, Gu X, et al. Periprocedural bridging anticoagulation: measuring the impact of a clinical trial on care delivery. Am J Med. 2019; 132 ( 109 ): e1 - e7. | |
dc.identifier.citedreference | Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019; 179: 1469. | |
dc.identifier.citedreference | Baumgartner C, de Kouchkovsky I, Whitaker E, Fang MC. Periprocedural bridging in patients with venous thromboembolism: a systematic review. Am J Med. 2019; 132 ( 6 ): 722 - 732.e7. | |
dc.identifier.citedreference | Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012; 141: e326S - e350. | |
dc.identifier.citedreference | Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non- surgical patients. J Thromb Haemost. 2005; 3 ( 4 ): 692 - 694. | |
dc.identifier.citedreference | Barnes GD, Kline- Rogers E. Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis. 2015; 39: 403 - 409. | |
dc.identifier.citedreference | Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373: 823 - 833. | |
dc.identifier.citedreference | Sjogren V, Grzymala- Lubanski B, Renlund H, Svensson PJ, Sjalander A. Safety and efficacy of bridging with low- molecular- weight heparin during temporary interruptions of warfarin: a Register- based cohort study. Clin Appl Thromb Hemost. 2017; 23: 961 - 966. | |
dc.identifier.citedreference | Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175(7):1163- 1168. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.